Curevac Stock Soars 14.29% on Patent Victory

On March 28, 2025, Curevac's stock surged 14.29% in pre-market trading, marking a significant rise in investor confidence.

Curevac has recently secured a pivotal victory in its patent dispute with BioNTech. The European Patent Office (EPO) has upheld the validity of Curevac's mRNA technology patent, dismissing BioNTech's opposition. This decision is a major win for Curevac, as it solidifies the company's intellectual property rights and strengthens its position in the mRNA technology market.

This legal triumph is expected to have a positive impact on Curevac's future prospects, as it removes a significant legal hurdle and allows the company to focus on advancing its mRNA-based therapies and vaccines. The ruling also sends a strong message to competitors, reinforcing Curevac's leadership in the field of mRNA technology.